FDA's NewAIGuidance Highlights Risksof Technology, Urges Early Sponsor Engagement
In its 23-page document, the regulator proposes a “risk-based credibility assessment framework” for using AI in the drug product life cycle. Among the …
Read the original at biospace.com ↗
- Topics
- HealthcareRegulation & PolicyGovernance & Risk Management
- Mentions
- FDA
- Tags
- AI Use Case
- Tracked via
- Google Alert “AI Risks”